3 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edemaeye disorder, macular degeneration, macular retinal edema, retinal degeneration, retinal disorderRecruitingPhase 22026-10-01NCT06962839
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorderActive, not recruitingPhase 32026-10-01NCT06531824
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)Arterial Occlusive Diseases, Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Infarction, Male Urogenital Diseases, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, chronic renal failure syndrome, coronary artery disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, ischemic disease, kidney disorder, kidney failure, metabolic disease, myocardial infarction, myocardial ischemia, peripheral arterial disease, peripheral vascular disease, urinary system disorder, vascular disorderRecruitingPhase 2 / Phase 32026-09-21NCT05485961